This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Flurbiprofen oral

Updated 2 Feb 2023 | NSAIDs


Oral formulations of flurbiprofen

Drugs List

  • flurbiprofen 100mg tablets
  • flurbiprofen 50mg tablets
  • Therapeutic Indications


    Ankylosing spondylitis
    Dysmenorrhoea (adjunctive treatment)
    Pain - mild to moderate
    Relief of migraine headache
    Rheumatoid disease
    Short term use in musculoskeletal disorders



    150 mg to 200 mg daily in two to four divided doses.
    The maximum daily dosage may be increased to 300 mg in divided doses.

    Initial dose: 100 mg
    Followed by 50 mg or 100mg every four to six hours.
    The maximum daily dosage should not exceed 300 mg.


    (See Dosage; Adult)


    Children aged 12 to 18 years
    (See Dosage; Adult)


    Children under 12 years
    Crohn's disease
    Hereditary fructose intolerance
    History of gastrointestinal bleeding
    History of gastrointestinal perforation
    History of peptic ulcer
    History of ulcerative colitis
    Peptic ulcer
    Severe cardiac failure
    Severe hepatic impairment
    Severe renal impairment
    Third trimester of pregnancy
    Ulcerative colitis

    Precautions and Warnings

    Females attempting to conceive
    Risk factors for cardiovascular disorder
    Cardiac impairment
    Cerebrovascular disorder
    Congestive cardiac failure
    Connective tissue disorder
    First trimester of pregnancy
    Glucose-galactose malabsorption syndrome
    Hepatic impairment
    History of gastrointestinal disorder
    Ischaemic heart disease
    Lactose intolerance
    Renal impairment
    Second trimester of pregnancy
    Severe dehydration
    Systemic lupus erythematosus

    NSAIDs may provoke or exacerbate asthma
    Advise ability to drive/operate machinery may be affected by side effects
    Consider other first line treatment options in the elderly
    Consider the need for combination therapy with gastroprotective agents
    Contains lactose
    Preparation contains sucrose
    Advise patient to take with or after food
    Discontinue if signs of gastro-intestinal bleeding occur
    Elderly - monitor for gastro-intestinal bleeding over initial 4 weeks
    May inhibit platelet aggregation - observe for signs of bleeding
    Monitor closely patient with a history of congestive cardiac failure
    Monitor for gastrointestinal bleeding following discontinuation of therapy
    Monitor renal function in patients with cardiac impairment
    Monitor renal function in patients with hepatic impairment
    Monitor renal function in patients with renal impairment
    Advise patients to report lower gastrointestinal bleeding
    Avoid concomitant drugs which may increase risk of gastrotoxicity/bleeding
    Discontinue if signs of gastro-intestinal ulceration occur
    High dose/long term use may increase risk of arterial thrombotic events
    May prolong bleeding time
    Risk of gastro-intestinal bleeding increased in the elderly
    Severe gastro-intestinal side effects may occur without warning
    Discontinue if drug-related rash or other hypersensitivity reactions occur
    Discontinue if patient is attempting to conceive
    Discontinue if severe skin reaction occurs
    Dosage must be individualised for each patient, especially children
    Maintain treatment at the lowest effective dose
    Reduce dose in elderly
    Start treatment at lowest recommended dose
    Avoid long term use
    Maintain treatment for the shortest possible duration
    May cause impaired fertility

    Pregnancy and Lactation


    Flurbiprofen is contraindicated in the third trimester of pregnancy.

    At the time of writing there is limited published information regarding the use of flurbiprofen during human pregnancy (Briggs et al, 2015). Studies that have used flurbiprofen on pregnant rats have shown a decrease in foetal survival and prolonged gestation (Briggs et al, 2015). Similar findings to other NSAIDs that have also been associated with spontaneous abortion. However Briggs (2015) also states the risk of flurbiprofen causing defects when used in pregnancy appears to be low. The manufacturer states to avoid the use of flurbiprofen during the first two trimesters of pregnancy unless the potential benefit to the mother outweighs the potential risk to the foetus.

    The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( ) or if this is unavailable at the backup site ( ).


    Use flurbiprofen with caution in breastfeeding.

    At the time of writing there is limited published information regarding the use of flurbiprofen during breastfeeding. The Drugs and Lactation Database (LactMed) states that flurbiprofen has a short half-life and therefore any insignificant amounts of the drug that may be excreted in breast milk is unlikely to cause harm to the infant. Hale (2015) also supports LactMed stating any trace of flurbiprofen excreted into breast milk is likely to be clinically insignificant. Schaefer (2015) states that there has been no toxic affects reported on the use of flurbiprofen in breastfeeding, however the manufacturer still suggests to avoid using flurbiprofen during breastfeeding.

    Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
    Specialist advice is available from the UK Drugs in Lactation Advisory Service at

    Side Effects

    Abdominal pain
    Abnormal liver function
    Aggravation of existing asthma
    Aplastic anaemia
    Arterial thrombosis
    Aseptic meningitis
    Bullous dermatoses
    Cardiac failure
    Cerebrovascular accident
    Epidermal necrolysis
    Erythema multiforme
    Exacerbation of colitis
    Exacerbation of Crohn's disease
    Exfoliative dermatitis
    Gastro-intestinal perforation
    Gastro-intestinal ulceration and bleeding
    Haemolytic anaemia
    Hypersensitivity reactions
    Interstitial nephritis
    Myocardial infarction
    Nephrotic syndrome
    Non-specific allergic reactions
    Optic neuritis
    Renal failure
    Stevens-Johnson syndrome
    Systemic lupus erythematosus
    Toxic epidermal necrolysis
    Ulcerative stomatitis
    Visual disturbances


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: February 2017

    Reference Sources

    Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment, 3rd edition (2015) ed. Schaefer, C., Peters, P. and Miller, R. Elsevier, London.

    Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, 10th edition (2015) ed. Briggs, G., Freeman, R. Wolters Kluwer Health, Philadelphia.
    Joint Formulary Committee. British National Formulary. 72nd ed. London: BMJ Group and Pharmaceutical Press; 2016.

    Paediatric Formulary Committee. BNF for Children 2016-2017. London: BMJ Group, Pharmaceutical Press, and RCPCH Publications; 2016.

    Medications and Mothers' Milk, Sixteenth Edition (2014) Hale, T and Rowe, H, Hale Publishing, Plano, Texas.

    Summary of Product Characteristics: Froben 50 mg Tablets. Mylan Products Limited. Revised September 2016.

    Summary of Product Characteristics: Froben 100 mg Tablets. Mylan Products Limited. Revised September 2016.

    US National Library of Medicine. Toxicology Data Network. Drugs and Lactation Database (LactMed).
    Available at:
    Last revised: 03 October 2015
    Last accessed: 11 January 2017

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.